Immune checkpoint inhibitors (ICIs) such as programmed cell death-1 and anti-programmed death-ligand 1 (PD-L1) inhibitors prolong the overall survival (OS) of patients with lung cancer (Ferrara et al. 2021; Zhou et al. 2020). This evidence concerns the gene CD274 and lung cancer.